MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias

Leukemia

Volumn 18, Issue 7, 2004, Pages 1231-1237

  Lasa, A ^a   Carnicer, M J ^a   Aventin A ^a   Estivill, C ^a   Brunet, S ^a   Sierra, J ^a   Nomdedeu J F ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute myeloid leukemia; CEBP methylation; Meis 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HOMEODOMAIN PROTEIN; MESSENGER RNA; PROTEIN MEIS 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; AZACITIDINE; DRUG DERIVATIVE; HYDROXAMIC ACID; MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CHIMERA; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MOLECULAR MECHANICS; POINT MUTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ACUTE DISEASE; BONE MARROW; CASE CONTROL STUDY; DNA METHYLATION; DRUG EFFECT; GENETICS; MYELOID LEUKEMIA; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ACUTE DISEASE; ADULT; AZACITIDINE; BONE MARROW; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA METHYLATION; DOWN-REGULATION; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 3142733632     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403377     Document Type: Article

References (25)

1. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukemia. Nat Rev Cancer 2002; 2: 502-551.
2. Yuan Y, Zhou T, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. RUNX1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutation. Proc Natl Acad Sci USA 2001; 98: 10398-10403.
3. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for Hox and Meis 1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001; 21: 224-234.
4. Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with HoxA9 in myeloid leukemia. Proc Natl Acad Sci USA 2001; 98: 13120-13125.
5. Imamura T, Morimoto A, Takanashi M, Hibi S, Sugimoto T, Ishii E et al. Frequent co-expression of HoxA9 and Meis 1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol 2002; 119: 119-121.
6. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis 1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 1995; 15: 5434-5443.
7. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada D, Nakamura T et al. Leukemia disease genes: large-scale cloning and pathway predictions. Nat Genet 1999; 23: 348-353.
8. Smith JE, Bollekens JA, Inghirami G, Takeshita K. Cloning and mapping of the MEIS 1 gene, the human homolog of a leukemogenic gene. Genomics 1997; 43: 99-103.
9. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for minimal residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003; 17: 2318-2357.
10. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
11. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nat Genet 1999; 23: 166-175.
12. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 2001; 21: 5577-5590.
13. Darzynkiewicz Z, Juan G. Analysis of DNA content and BrdUrd incorporation. In: Robinson P, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Stewart C, Tanke H, Wheeless L (eds). Curr Protocols Cytometry, New York, NY: Current Protocols/Wiley-Liss, 1998, Section 7.7, pp 7.7.1-7.7.6.
14. Muñoz L, Nomdedeu JF, Villamor N, Munoz L, Guardia R, Colomer D et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76-82.
15. Cameron ER, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
16. Toyooka S, Carbone M, Toyooka KO, Bochetta M, Shivapurkar N, Minna JD et al. Progressive aberrant methylation of the RASSF1 A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002; 21: 4340-4344.
17. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the down-regulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 2002; 99: 10084-10089.
18. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and hinds mSin3A through its oligomerization domain. Mol Cell Biol 2001; 21: 6470-6483.
19. Hug BA, Lee S, Kinsler E, Zhang J, Lazar MA. Cooperative function of RUNX1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res 2002; 62: 2906-2912.
20. Rangatia J, Vangala R, Treiber N, Zhang P, Radomska H, Tenen DG et al. Downregulation of c-Jun expression by transcription factor C/EBPα is critical for granulocyte lineage commitment. Mol Cell Biol 2002; 22: 8681-8694.
21. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. RUNX1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
22. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 2003; 4: 197-207.
23. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766-2769.
24. Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 2003; 17: 350-358.
25. Di Croce L, Raker VA, Corsaro MM, Fazi F, Fanelli M, Faretta M et al. Methyltransferase recruitment and DNA hypermethylation of target promoter by an oncogenic transcription factor. Science 2002; 295: 1079-1082.